Achillion to Report Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on February 20, 2013
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130219:nGNXUXEVIa NEW HAVEN, Conn., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release fourth quarter and year-end 2012 financial results on Wednesday, February 20, 2013, after the market closes. Achillion will also host a conference call and live webcast to discuss these financial results and to provide an update on the Company's hepatitis C (HCV) development programs that afternoon at 5:00 p.m. EST. To participate in the conference call, please dial (877) 266-0482 in the U.S. or (631) 291-4567 for international callers. A live audio webcast of the call will be accessible at www.achillion.com http://www.globenewswire.com/newsroom/ctr?d=10022281&l=2&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com , under the News Center section of the website. Please connect to Achillion's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. A replay of the webcast will be available on www.achillion.com http://www.globenewswire.com/newsroom/ctr?d=10022281&l=3&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com . Alternatively, a replay of the conference call can be accessed beginning at approximately 8:00 p.m. EST on February 20, 2013, through 11:59 p.m. ET on February 27, 2013 by dialing (855) 859-2056 or (404) 537-3406 for international callers. The replay passcode is 13062862. About Achillion Pharmaceuticals Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com http://www.globenewswire.com/newsroom/ctr?d=10022281&l=5&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com or call 1-203-624-7000. CONTACT: Company Contact: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 firstname.lastname@example.org Media: Christin Culotta Miller Ogilvy PR Tel. (646) 229-5178 email@example.com Investors: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 firstname.lastname@example.org Investors: Seth Lewis The Trout Group, LLC Tel. (646) 378-2952 email@example.com